The Pink Sheet takes an infographic look at South Korea's clinical trial trends in 2022 to illustrate how the country's biopharma R&D is developing and how activities are recovering in the post-pandemic situation. One key takeaway is that approvals for trial starts have fallen back to pre-COVID levels, suggesting a falling off of activity related to drugs and vaccines for the virus.

China's Center for Drug Evaluation has finalized new guidelines that stipulate sponsors of randomized controlled clinical studies should more closely consider patient needs and experience when designing trials, including a consideration of likely future changes in standard therapies.